OncoDNA raised EUR 19 million from Vesalius Biocapital, Swisscanto Invest, and SFPI-FPIM. Verve Ventures contributed EUR 1.8 million in a later closing, its second investment in Belgium.

OncoDNA focuses on cancer diagnostic testing of solid tumor biopsies and blood samples. The company has developed a proprietary database of cancer treatments, which provides oncologists with the best options for their patients.

“I have several examples where it allowed me to identify precisely targeted therapeutic approaches that helped patients who otherwise would have had just a very short life expectancy”, says Dr. Jean-Loup Mouysset, a renowned oncologist and Ashoka fellow based in Aix-en-Provence. Read our interview with him here. 

Jean-Pol Detiffe, founder and CEO of OncoDNA, has already successfully built and exited a testing company prior to funding OncoDNA, as he explains in our interview.

“The strong management team has achieved very good traction in a very large and growing market”, says Michael Lütolf, Investment Manager for Verve Ventures.

The funds will be used to develop OncoDNA’s bioinformatics platform, to enlarge its team and grow internationally.